Cytosorbents Corp
NASDAQ:CTSO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cytosorbents Corp
Cost of Revenue
Cytosorbents Corp
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cytosorbents Corp
NASDAQ:CTSO
|
Cost of Revenue
-$10.6m
|
CAGR 3-Years
9%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-17%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cost of Revenue
-$6.4B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-11%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Cost of Revenue
-$1.4B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-8%
|
|
|
Stryker Corp
NYSE:SYK
|
Cost of Revenue
-$8.9B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-10%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Cost of Revenue
-$19.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-8%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cost of Revenue
-$3.4B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-16%
|
|
Cytosorbents Corp
Glance View
CytoSorbents Corp. engages in the critical care immunotherapy, investigation, and commercialization of blood purification technology. The company is headquartered in Monmouth Junction, New Jersey and currently employs 221 full-time employees. The company went IPO on 2005-06-17. The firm is engaged in the treatment of life-threatening conditions in the intensive care (ICU) and cardiac surgery using blood purification via its polymer adsorption technology. The firm's lead product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy and pancreatitis. Its other products include animal-targeted VetResQ, DrugSorb-ATR and ECOS-300CY. The firm's product candidates under development includes CytoSorb XL, BetaSorb, ContrastSorb, DrugSorb, HemoDefend-RBC, HemoDefend-BGA, K+ontrol, and others consist of a cartridge containing adsorbent and porous polymer beads.
See Also
What is Cytosorbents Corp's Cost of Revenue?
Cost of Revenue
-10.6m
USD
Based on the financial report for Dec 31, 2025, Cytosorbents Corp's Cost of Revenue amounts to -10.6m USD.
What is Cytosorbents Corp's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-17%
Over the last year, the Cost of Revenue growth was -1%. The average annual Cost of Revenue growth rates for Cytosorbents Corp have been 9% over the past three years , 1% over the past five years , and -17% over the past ten years .
